Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
Open Access
- 20 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 24 (1), 103-114
- https://doi.org/10.1007/s10147-018-1319-y
Abstract
Background This was the first large-scale prospective observational Japanese study evaluating the safety and efficacy of bevacizumab combined with paclitaxel and carboplatin for newly diagnosed advanced ovarian cancer. Methods Patients were prospectively enrolled in the primary analysis cohort if they had Stage III or IV epithelial ovarian/fallopian tube/primary peritoneal cancer and were scheduled to receive paclitaxel plus carboplatin every 3 weeks in Cycles 1–6 and bevacizumab every 3 weeks in Cycles 2–22. Primary endpoints were bevacizumab-specific adverse events and adverse events ≥ Grade 3. Secondary endpoints were progression-free survival (PFS) and the response rate. Results Among 346 patients enrolled, 293 patients formed the primary analysis cohort. Regarding bevacizumab-specific adverse events ≥ grade 3, incidence rates of thromboembolic events (1.4%), gastrointestinal perforation (0.3%), fistula (0.7%), wound dehiscence (0%), and bleeding (0%) were very low. While incidence rates of hypertension (23.2%) and proteinuria (12.6%) were high, all such events were tolerable. No patient with prior bowel resection developed perforation or fistula. Median PFS was 16.3 months (95% CI 14.5–18.9). The response rate was 77.5% (95% CI 67.4–85.7). The response rate was 63.6% in patients with clear cell carcinoma, which tended to be better than previously reported. The median platinum-free interval was 11.5 months, and the platinum-resistant recurrence rate was 24.5%. Conclusions Combining bevacizumab with chemotherapy was tolerable and efficacy was acceptable in Japanese patients with advanced epithelial ovarian cancer. Bevacizumab seems to reduce platinum-resistant recurrence and is promising for clear cell carcinoma.Keywords
Funding Information
- Chugai Pharmaceutical Co., Ltd.
This publication has 23 references indexed in Scilit:
- New insights into ovarian cancer pathologyAnnals Of Oncology, 2012
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapyAnnals Of Oncology, 2012
- Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?Journal of Experimental & Clinical Cancer Research, 2012
- Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancerLung Cancer, 2012
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian CancerThe New England Journal of Medicine, 2011
- A Phase 3 Trial of Bevacizumab in Ovarian CancerThe New England Journal of Medicine, 2011
- Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the OvaryMolecular Cancer Therapeutics, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancersGynecologic Oncology, 2008
- Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With GefitinibJournal of Clinical Oncology, 2006